国际眼科纵览 ›› 2021, Vol. 45 ›› Issue (4): 330-334.doi: 10.3760/ cma.j.issn.1673-5803.2021.04.012

• 综述 • 上一篇    下一篇

眼用抗血管内皮生长因子水凝胶药物缓释系统的研究进展

孟捷 朱蓉嵘   

  1. 南通大学附属医院眼科,江苏南通 226000
  • 收稿日期:2020-12-25 出版日期:2021-08-22 发布日期:2021-08-30
  • 通讯作者: 朱蓉嵘,Email:zrreye@126.com E-mail:zrreye@126.com
  • 基金资助:
    南通市科技项目(JCZ19089)

Progress on hydrogel anti-vascular endothelial growth factor drug delivery system in Ophthalmology

Meng Jie, Zhu Rongrong   

  1. Department of Ophthalmology, Affilated Hospital of Nantong University, Nantong Jiangsu 226000, China
  • Received:2020-12-25 Online:2021-08-22 Published:2021-08-30
  • Contact: Zhu Rongrong, Email:zrreye@126.com E-mail:zrreye@126.com
  • Supported by:
    Nantong Science and Technology Project (JCZ19089)

摘要: 水凝胶具有优良的生物相容性及与玻璃体类似的光学和流变性,能比较容易地进行玻璃体注射,且具有药物缓释的特点,可以作为抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物缓释系统载体应用于各种视网膜脉络膜疾病的治疗。近年来,已有多种类型的水凝胶载体在动物模型中研制成功, 包括天然和人工合成水凝胶,其中一些可在眼内持续释放贝伐单抗、康柏西普等抗VEGF 药物最长达 90 天,且眼内无明显炎性反应。抗VEGF药物从水凝胶中的释放一般经过初始释放阶段、扩散释放阶段和降解释放阶段。如何控制其在水凝胶中的缓释速率、提高载药量以及延长水凝胶在玻璃体内的降解时间等是现阶段亟待解决的问题。(国际眼科纵览,2021, 45: 330-334)

关键词: 水凝胶, 抗血管内皮生长因子, 药物缓释系统

Abstract: The hydrogel has excellent biocompatibility and similar optical and rheological properties to the vitreous body. It can be easily injected into the vitreous cavity and has the characteristics of sustained drug release. It can be used as a carrier for anti-vascular endothelial growth factor (VEGF) drug delivery system for the treatment of various retinal and choroidal diseases. In recent years, many types of hydrogel carriers have been successfully developed in animal models, including natural and synthetic hydrogels, some of which can sustainably release bevacizumab, conbercept and other anti-VEGF drugs in the eye. The release of anti-VEGF drugs from hydrogels generally goes through the initial release stage, diffusion release stage and degradation release stage. How to control the release rate in the hydrogel, increase the drug loading and prolong the degradation time of the hydrogel in the vitreous are urgent problems to be solved at the present stage. (Int Rev Ophthalmol, 2021, 45: 330-334)

Key words: hydrogel, anti-vascular endothelial growth factor, drug delivery system